Explanted malignancies after lung transplantation: the University of Michigan experience

Jarred R. Mondoñedo, Tao Huang, Jules Lin and Elliot Wakeam

Section of Thoracic Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA
Department of Pathology, University of Michigan, Ann Arbor, MI, USA

Corresponding author. Section of Thoracic Surgery, University of Michigan, 1500 E Medical Center Dr., Ann Arbor, MI 48109, USA. Tel: +1-734-232-4940; fax: +1-734-615-2656; e-mail: ewakeam@med.umich.edu (E. Wakeam).

Received 20 March 2022; received in revised form 1 July 2022; accepted 23 July 2022

Abstract

The management of patients with an explanted malignancy after lung transplantation is not well understood. We reviewed our institutional experience and outcomes at a single academic medical centre between December 1997 and April 2021 for patients with malignancies of all histologic types identified on explant pathology. Primary lung cancers were reclassified using the 8th Edition TNM staging and the 2021 World Health Organization histologic classification of lung cancers. Of the 733 patients undergoing lung transplantation, 15 (2.05%) were found to have malignancy on the explanted lungs, including 6 (0.82%) primary lung cancers. Four patients were found to have early-stage lung cancers, while 2 patients had advanced-stage IV disease. Survival ranged from 0 to 109 months for the entire cohort with median 23.2 [49.9] months in those with primary lung cancers. There were 2 recurrences following explanted stage I (15 months) and stage IV (53 months) diseases. Other explant pathologies included carcinoid tumourlets in 6 patients, lymphoma in 2 and metastatic leiomyosarcoma in 1. In conclusion, explanted lung malignancies are an infrequent but significant finding on explant pathology. Further data are needed to better characterize and stratify this patient cohort.

Keywords: Lung transplant • Lung cancer • Patient survival

INTRODUCTION

Lung transplantation is an effective therapeutic modality for patients with end-stage pulmonary failure, commonly encountered as a result of chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Both conditions, however, are associated with an increased risk of primary pulmonary malignancies, classically considered to be a contraindication to transplantation. Detection of suspicious nodules can be challenging in the presence of widespread fibrotic changes and parenchymal destruction, such that unexpected malignancies are occasionally diagnosed histologically on explanted lungs. In this study, we reviewed our individual institutional experience and outcomes associated with all explanted malignancies after lung transplantation, including pathological reclassification of primary lung cancers.

PATIENTS AND METHODS

We conducted a retrospective chart review including all patients undergoing lung transplantation at a single academic medical centre during the study period of December 1997 to April 2021. Patients found to have an explanted malignancy of any histologic classification were identified by sequentially examining all pathology reports. All cases of primary lung cancers identified were reviewed by a pulmonary pathologist with re-classification and re-staging using the 2021 World Health Organization (WHO) histologic classification of lung cancers and the 8th Edition TNM staging.

Survival and recurrence were defined as the time from lung transplantation to the last follow-up or to the date of radiographically identified or biopsy-proven recurrent malignancy, respectively. Standard follow-up surveillance was performed per the National Comprehensive Cancer Network (NCCN) algorithm. Data presented as median [interquartile range] unless stated otherwise.

This retrospective study was deemed exempt by the University of Michigan institutional review board (HUM00083784).

RESULTS

Of the 733 patients undergoing lung transplantation, 15 (2.05%) were found to have a malignancy on explant pathology, including 6 (0.82%) primary lung cancers (Table 1). Adenocarcinoma was the most common histologic subtype (n = 4) of the primary lung cancers, followed by squamous cell carcinoma (n = 2). Stage
Over the study period, 2.04% of patients were found to have a malignancy of any kind, including primary lung cancers, carcinoid tumourlets, lymphoma and other metastatic diseases. Our incidence rate of 0.82% for explanted lung cancers is consistent with estimates of roughly 1–2% in recent case series [1–6].

While earlier multicentre studies have demonstrated the feasibility of long-term survival in patients with more indolent subtypes of lung cancer, it is uncertain whether current histologic classifications and TNM staging for lung adenocarcinomas as applied here will further divide patients into different prognostic groups. A recent study [1] stratified survival outcomes by stage at explant and reported overall survival (OS) of 87%, 26% and 17% for patients with stage I disease at 1, 3 and 5 years, respectively, while patients with stage III and IV diseases died within 1 year. Others [2–4] have similarly reported a reduced OS when a malignancy was identified on explant pathology, where moderate to poorly differentiated malignancies had a worse prognosis. In contrast, a study from Vienna [5] demonstrated a remarkable 5-year OS of 90.5% for patients with explanted lung cancer (n = 11) compared to 58.9% for all other patients.

We observed a wide range of survival including disease recurrence in 2 patients. Notably, 1 patient in our cohort who underwent bilateral transplantation with biopsy-proven adenocarcinoma was surviving at follow-up at 7 years despite cancer recurrence, while another survived >5 years after lung transplantation with metastatic leiomyosarcoma discovered on explant pathology. Patients with carcinoid tumourlets also appeared to do well. However, given the relatively few numbers of patients in each of these studies, more general conclusions are difficult to draw. To better characterize patient outcomes, guide post-transplant patient management and understand outcomes based on pathologic subtype, we have initiated and are currently recruiting for a multi-institutional study for these patients, a data collection template is appended in Supplementary Material, Table S1.

**Limitations**

Nevertheless, our data must be interpreted in light of several limitations. The small number of cases precludes advanced statistical

### Table 1: Patient characteristics and explant pathologies

| Age, sex | Smoking (pack years) | Indication | LAS | Transplant | Explant pathology | Stage | CT (months) | Recurrence (months) | Survival (months) |
|----------|----------------------|------------|-----|------------|-------------------|-------|-------------|--------------------|------------------|
| 61, M    | Former (20)          | PAH        | -   | Single     | Squamous cell T1b N0 Mx | IA2   | 30          | 15                 | 18               |
| 58, F    | Former (40)          | COPD       | -   | Single     | Carcinoid tumourlets | 12    | -           | 0                  | 0                |
| 33, F    | Former (20)          | COPD       | -   | Bilateral  | Adenocarcinoma T1a N0 Mx | IA1   | 48          | -                  | 2                |
| 56, F    | Former (70)          | COPD       | -   | Single     | Adenocarcinoma T3 N1 Mx | IIIA  | 30          | -                  | 2                |
| 45, F    | Never smoker         | BO         | 33.42| Bilateral  | Carcinoid tumourlets | 1     | -           | 14                 | 14               |
| 40, F    | Former (22)          | COPD       | 38.87| Bilateral  | Adenocarcinoma       | -     | 3a          | -                  | 27               |
| 60, F    | Former (100)         | COPD       | 31.28| Single     | Carcinoid tumourlets | 3b    | -           | 98                 |                  |
| 45, F    | Former (8)           | ILD        | 34.00| Single     | Metastatic leiomyosarcoma | 14    | -           | 64                 |                  |
| 52, F    | Former (30)          | BO         | 43.53| Bilateral  | Carcinoid tumourlets | 7     | -           | 109c               |                  |
| 46, M    | Former (1)           | ILD        | 42.85| Bilateral  | Adenocarcinoma        | IIIA  | 2a,b        | 53                 | 92c               |
| 66, M    | Never smoker         | ILD        | 37.27| Bilateral  | Squamous cell T1a N0 M0 | IA1   | 19          | -                  | 66c               |
| 53, F    | Never smoker         | CF         | 40.08| Bilateral  | Carcinoid tumourlets | 5     | -           | 31c                |                  |
| 61, F    | Never smoker         | ILD        | 42.26| Bilateral  | MALT lymphoma         | 2     | -           | 6                  |                  |
| 49, F    | Never smoker         | CF         | 39.87| Bilateral  | Carcinoid tumourlets | 2     | -           | 15c                |                  |
| 48, M    | Never smoker         | ILD        | 42.66| Bilateral  | MALT lymphoma         | 0     | -           | 5c                 |                  |

*Tissue biopsy.

TPreoperative PET scan.

*Living.

F: female; M: male; LAS: lung allocation score; BO: bronchiolitis obliterans; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; MALT: mucosa-associated lymphoid tissue; PAH: pulmonary arterial hypertension.
modelling or does it allow for a robust comparator group. Given the duration of the study period considered here, there was also inadequate staging in some patients early on including few patients undergoing preoperative PET scans. Similarly, although the pathology was reviewed and updated for this study, the analysis was limited by the length of time and availability, and while a detailed analysis of pathological subsets (such as outcomes for lepidic adenocarcinomas) would no doubt be extremely useful for clinical decisions, the small number of patients precluded such an analysis. However, clinical selection of these patients is critical and our results merely represent what centres considering transplant in this population might expect among an uncommon but important subset of patients.

CONCLUSION

In summary, review of our institutional experience suggests that explanted malignancies identified after lung transplant are relatively infrequent, but significant findings. Larger, multicentre studies are needed with a focus on obtaining better pathological classification of explanted lung cancers and prospective data on both overall survival and lung cancer-specific survival.

SUPPLEMENTARY MATERIAL

Supplementary material is available at ICVTS online.

ACKNOWLEDGEMENTS

The authors would like to acknowledge Dr. Chaehwa Kim for assistance in reviewing primary lung cancer pathologies and Grant Chappell for assistance with the development of the REDCap database. We are grateful for the helpful contribution from Drs. Rishindra M. Reddy, William R. Lynch, Andrew C. Chang, Kiran H. Lagisetty, Kevin Chan and Michael P. Combs in the preparation of this article.

Funding

This work was supported by intramural funds in the Department of Surgery, Section of Thoracic Surgery at the University of Michigan.

Conflict of interest: none declared.

Reviewer information

Interactive CardioVascular and Thoracic Surgery thanks Davide Tosi, Matthieu Thumerel, Luca Voltolini and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.

REFERENCES

[1] Ahmad U, Hakim AH, Tang A, Tong MZ, Bribiesco A, Budev M et al. Patterns of recurrence and overall survival in incidental lung cancer in explanted lungs. Ann Thorac Surg 2019;107:891–6.
[2] Grewal AS, Padera RF, Boukedes S, Divo M, Rosas IO, Camp PC et al. Prevalence and outcome of lung cancer in lung transplant recipients. Respir Med 2015;109:427–33.
[3] Nakajima T, Cypel M, de Perrot M, Pierre A, Waddell T, Singer L et al. Retrospective analysis of lung transplant recipients found to have unexpected lung cancer in explanted lungs. Semin Thorac Cardiovasc Surg 2015;27:9–14.
[4] Panchabhai TS, Arrossi AV, Patil PD, Bandyopadhyay D, Budev MM, McCurry KR et al. Unexpected neoplasms in lungs explanted from lung transplant recipients: a single-center experience and review of literature. Transplant Proc 2018;50:234–40.
[5] Klikovits T, Lambers C, Ghansim B, Dome B, Murakoezy G, Zochbauer-Müller S et al. Lung transplantation in patients with incidental early stage lung cancer-institutional experience of a high volume center. Clin Transplant 2016;30:912–7.
[6] Strollo DC, Dacic S, Ocak I, Pilewski J, Bermudez C, Crespo MM. Malignancies incidentally detected at lung transplantation: radiologic and pathologic features. AJR Am J Roentgenol 2013;201:168–16.

Table 2: Meta-analysis of single-centre reports

| Study            | Size | Incidence, n (%) | Histopathology | Survival | Recurrence, n (%) |
|------------------|------|------------------|----------------|----------|-------------------|
| Strollo et al. [6] | 759  | 22 (2.90)        | 13 (I/III), 2 (III), 2 (IV), 3 (metastases) | –         | –                 |
|                  |      |                  | 2 (I), 4 (III) |          | 36±, 6 months (I) |
|                  |      |                  |                |          | 16.5 (7–25) months (III) |
| Grewal et al. [2] | 462  | 6 (1.30)         | 4 (I), 5 (II)  | 36±, 6 months (I) | –     |
|                  |      |                  | 1 (III), 3 (IV) |          | 16.5 (7–25) months (III) |
| Nakajima et al. [3] | 853  | 13 (1.52)        | 10 (I), 1 (II) | Median 339 days | 9 (69.2) |
|                  |      |                  |                | 3-Year OS 11% |       |
| Klikovits et al. [5] | 1262 | 11 (0.87)        | 15 (I), 8 (II) | 5-Year OS 90.5% | 0     |
|                  |      |                  | 3 (III), 1 (IV) |          |                   |
| Panchabhai et al. [4] | 1303 | 24 (1.84)        | 15 (I), 10 (II) | 1-, 3- and 5-year OS 78, 18, 14% | 8 (33.3) |
|                  |      |                  | 2 (III), 2 (IV) |          |                   |
| Ahmad et al. [1]  | 1710 | 31 (1.81)        | 1 (metastasis), 1 (MALT) |          |                   |

*Living.
MALT: mucosa-associated lymphoid tissue.